Navigation Links
ERT Announces the Appointment of Joel Morganroth, MD as Interim CEO
Date:12/21/2010

PHILADELPHIA, Dec. 21, 2010 /PRNewswire-FirstCall/ – ERT (Nasdaq: ERES), a global provider of technology and services to the pharmaceutical, biotechnology and medical device industries, today confirmed that the effective date of the previously announced retirement of Dr. Michael J. McKelvey, its President and CEO, is December 21, 2010.

Dr. Joel Morganroth, currently ERT's Chairman and Chief Scientific Officer, has also been elected by the Board as President and CEO until ERT hires a permanent CEO.  Dr. Morganroth has served as the Chairman of ERT's Board of Directors since 1999 and as Chief Scientific Officer since April 2006. He previously served as the company's Chief Executive Officer from 1993 to March 2001 and also has consulted for ERT since 1977. Dr. Morganroth is also a globally recognized cardiologist and clinical researcher and has had more than 10 years' experience as a medical review officer/expert for the U.S. Food and Drug Administration (FDA).

Dr. Morganroth commented,

"We thank Dr. McKelvey for his years of service and wish him well in his future endeavors."  

"ERT is a leading provider of innovative solutions and is well positioned for continued growth. In my expanded role, I will continue to leverage my experience and knowledge of the organization and domain expertise to strengthen our position in clinical research associated with Cardiac Safety, Respiratory and electronic Patient Reported Outcomes [ePRO]. With our superb management team, we will continue our goal of enhanced growth through the exciting development of adjacent markets."

For further information on ERT and its technology and services please email info@ert.com, call +1 215 972 0420 or visit www.ert.com.

For further press information please contact Fiona Robinson, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom. Phone +44 1477 539539, Fax +44 1477 539540, Email ert@scottpr.co.uk.

About ERTBased in Philadelphia, PA, eResearchTechnology, Inc. (www.ert.com) is a global provider of technology and services to the pharmaceutical, biotechnology and medical device industries.  The Company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. It is also a leading provider of centralized respiratory technology and services to evaluate pulmonary function efficacy and safety in clinical development.  Sponsors can further use the Company's solutions to streamline the clinical trials process by automating the collection, analysis, and distribution of ePRO clinical data using multi-mode technology in all phases of clinical development as well as selected medical devices for the clinical trials and healthcare industries.

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties, which could cause actual results to differ materially from those expressed or implied from such statements.  These risks and uncertainties include, without limitation, the Company's ability to obtain new contracts, variability in size, scope and duration of projects, integration of acquisitions, competitive factors, technological development, market demand, and other factors described in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.Media Contacts:Fiona Robinson

John BlakeleyThe Scott Partnership

ERTTel: +44 1477 539539

+1 215 972 0420ert@scottpr.com

jblakeley@ert.com
'/>"/>

SOURCE ERT
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. INVO Bioscience Announces First Shipments of INVOcell Into Bolivia
2. MAP Pharmaceuticals Announces Completion of LEVADEX™ Open-Label Safety Trial
3. Bellicum Pharmaceuticals Announces $3 Million in Convertible Note Funding
4. China Botanic Announces Progress on its SOX 404 Compliance Program
5. Lotus Pharmaceuticals Announces Change of Directors
6. Boston Scientific Announces Election of Dr. Kristina M. Johnson to its Board of Directors
7. Lilly Announces Completion of Avid Acquisition and FDA Priority Review for florbetapir
8. Centocor Ortho Biotech Inc. Announces NDA Submission for Abiraterone Acetate for the Treatment of Metastatic Advanced Prostate Cancer
9. Sysmex America Announces Executive Promotions
10. PharMEDium Announces Propofol, Ready-to-Use, Single Patient, Syringe Service for Operating Room Anesthesia
11. SurgiCount Medical Announces the Successful Implementation of the Safety-Sponge® System at the University of Michigan Health System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... 2017  nThrive™, an independent Patient-to-Payment? solutions company ... leadership at the 2017 HIMSS Conference. The company ... from KLAS. nThrive will host a ... market trends shape the holistic, integrated revenue cycle ... Patient Access solution. The panel will reveal how ...
(Date:2/18/2017)... WASHINGTON, N.Y. , Feb. 17, 2017 /PRNewswire/ ... firm dedicated to protecting the rights of victims ... problems have prompted regulators to call for better ... in 1990. Safety concerns involving power ... Drug Administration (FDA) to investigate how hospitals report ...
(Date:2/17/2017)... Cryoablation, Electrical, Endometrial Hydrothermal, Laser/Light, Microwave, Radiofrequency, Ultrasound, Cardiovascular, Gynaecology, Musculoskeletal, ... to grow at a CAGR of 9.4% from 2017-2022 and CAGR ... a CAGR of 9.5% from 2017 to 2027. The market is ... ... you Read on to discover how you can exploit the ...
Breaking Medicine Technology:
(Date:2/20/2017)... ... February 20, 2017 , ... Best Doctors® and IBM ... benefit for companies that want to help members of their workforce battling cancer. ... access to Watson’s suite of oncology offerings for insights on cancer treatment options, ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... providers and health plan partners, announced during the 2017 Annual HIMSS Conference ... care coordination for diabetic patients and integrating eye care into mainstream healthcare ...
(Date:2/19/2017)... ... February 19, 2017 , ... "At your ... care, and MEDfx and the Delaware Health Information Network (DHIN) have partnered to ... nation’s first state-wide health information exchange, DHIN stores and shares real-time health data ...
(Date:2/18/2017)... ... February 17, 2017 , ... ... drvallecillos.com , Beverly Hills plastic surgeon Dr. Glenn Vallecillos experiments ... Dr. Vallecillos says, "Traditionally, plastic surgery has been centered around that idea that ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... kept pace. Enovate Medical has introduced an innovative workstation designed to reduce nursing ... nurses, the Encore Mobile EHR Workstation offers a lightweight, highly mobile, multi-functional alternative ...
Breaking Medicine News(10 mins):